Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in Its Phase I/II Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. announced that, as per protocol design, it has voluntarily paused new patient enrollment in the company’s Phase I/II trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas.